Ondansetron Ondansetron 4 MG Oral Tablet
1 INDICATIONS AND USAGE Ondansetron is indicated for the prevention of nausea and vomiting associated with: • highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 • initial and repeat courses of moderately emetogenic cancer chemotherapy • radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron is also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron is a 5-HT 3 receptor antagonist indicated for the prevention of: • nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 . ( 1 ) • nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. ( 1 ) • nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. ( 1 ) • postoperative nausea and/or vomiting. ( 1 )
Glenmark Pharmaceuticals Inc., USA
OVAL WHITE 4 G1
4 G1 OVAL WHITE
Related Pills
ondansetron 4 MG Disintegrating Oral Tablet
Glenmark Pharmaceuticals Inc., USA
Ondansetron Ondansetron 4 MG Oral Tablet
Glenmark Generics Inc., USA
Ondansetron Ondansetron 8 MG Disintegrating Oral Tablet
Glenmark Generics Inc., USA
Ondansetron Ondansetron 4 MG Oral Tablet
Glenmark Generics Inc., USA
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING
ONDANSETRON Tablets, USP • 4 mg (
ONDANSETRON hydrochloride, USP (dihydrate) equivalent to 4 mg of
ONDANSETRON), are white, oval, standard convex, film-coated tablets with ‘4’ on one side and ‘G1’ logo on the other side in: Bottles of 30 tablets (NDC 68462-105-30). Carton of 3 tablets (contains 1 card of 3 unit-of-use blisters) NDC 68462-105-33. 8 mg (
ONDANSETRON hydrochloride, USP (dihydrate) equivalent to 8 mg of
ONDANSETRON), are yellow, oval, standard convex, film-coated tablets with ‘8’ on one side and ‘G1’ logo on the other side in: Bottles of 30 tablets (NDC 68462-106-30). Carton of 3 tablets (contains 1 card of 3 unit-of-use blisters) NDC 68462-106-33 Bottles: Store at 20ºC to 25ºC (68ºF to 77ºF) [see USP Controlled Room Temperature]. Protect from light. Dispense in a tight, light-resistant container as defined in the USP. Cartons: Store at 20ºC to 25ºC (68ºF to 77ºF) [see USP Controlled Room Temperature]. Protect from light. Store blister in carton.
ONDANSETRON Orally Disintegrating Tablets, USP • 4 mg (as 4 mg
ONDANSETRON base) are white, circular, flat faced, uncoated tablets with ‘G’ engraved on one side and ‘4’ on the other side in: Carton of 30 tablets (contains 3 cards of 10 unit-of-use blisters) NDC 68462-157-13 • 8 mg (as 8 mg
ONDANSETRON base) are white, circular, flat faced, uncoated tablets with ‘G’ engraved on one side and ‘8’ on the other side in: Carton of 10 tablets (contains 1 card of 10 unit-of-use blisters) NDC 68462-158-11 Carton of 30 tablets (contains 3 cards of 10 unit-of-use blisters) NDC 68462-158-13 Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].
More pills like OVAL 4 G1